



## **VentriPoint Diagnostics Ltd. Appoints Dr. Robyn Barst to Scientific Advisory Board**

Tuesday, April 26, 2011

**SEATTLE, WASHINGTON--(Marketwire - April 26, 2011)** - VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX VENTURE:VPT)(PINK SHEETS:VPTDF) – is pleased to announce that Dr. Robyn J. Barst, Professor Emeritus of Pediatrics, Columbia University, has agreed to join the Company's Scientific Advisory Board.

"Dr. Barst has an extensive clinical and research experience in Pulmonary Hypertension, having been the Director of the Pulmonary Hypertension Center at Columbia University for over 25 years," Dr. George Adams states. "We believe that Dr. Barst will help propel the progress of the VMS application in pulmonary hypertension diagnostics, a market which is valued at well over \$1 billion." VentriPoint's pulmonary hypertension database is presently undergoing internal testing and is expected to be ready for clinical validation this summer. Dr. Barst will be assisting the Company in identifying clinical research sites.

Dr. Barst received her undergraduate degree from the University of Rochester, Rochester, NY and her medical degree (Alpha Omega Alpha and the Distinguished Medical Alumnus Award of the School of Medicine) from the University of North Carolina, Chapel Hill, NC. She completed a residency in pediatrics, and two fellowships in pediatric cardiology and pulmonary medicine at Columbia University College of Physicians & Surgeons in New York, NY. Following her training, Dr. Barst was recipient of the AHA Clinician-Scientist Award and the NHLBI Clinical Investigator Award.

Dr. Barst founded the first pediatric and adult pulmonary hypertension center in 1982 at Columbia University and served as its director until 2008. She serves as a scientific advisor to pharmaceutical companies worldwide developing novel drugs for pulmonary hypertension. She is a consultant to the FDA, the EMEA and the NHLBI. She also served as Chair of the AHA's Council on Cardiovascular Disease in the Young.

"I welcome the opportunity to serve on the Scientific Advisory Board of VentriPoint," states Dr. Barst. "I believe VentriPoint's VMS™ presents a solid opportunity, which could prove preferable in many situations where MRI and/or contrast ultrasound cannot be used."

### **About VentriPoint Diagnostics Ltd:**

VentriPoint creates diagnostic systems to monitor patients with heart disease, the number one cause of death in developed countries. The VMS is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application with additional applications in process to enable monitoring of all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a \$10 Billion market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS diagnostic tool and a 510(k) submission is currently being reviewed by the U.S. Federal Drug Administration. For further information about VentriPoint go to [www.ventripoint.com](http://www.ventripoint.com) .

**Cautionary Note Regarding Forward-Looking Statements** - Certain statements contained herein constitute forward-looking statements, including statements concerning the anticipated closing date of the Offering and the anticipated use of proceeds. We believe the expectations reflected in those forward-looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included herein should not be unduly relied upon. Closing could be delayed if VentriPoint cannot obtain necessary regulatory approvals within anticipated timelines and will not be completed unless certain conditions customary for transactions of this kind are satisfied. The forward-looking statements included in this press release are made as of the date of this press release and VentriPoint disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

**For further information contact:**

Ventripoint Diagnostics .  
George Adams  
President & CEO  
Ph: (403) 283-0221  
Fax: (403) 283-2309  
[info@ventripoint.com](mailto:info@ventripoint.com)  
[www.ventripoint.com](http://www.ventripoint.com)

The Howard Group Inc.  
Peter Weichler/Dave Burwell  
Investor Relations  
Toll Free: 1-888-221-0915  
Phone: (403) 221-0915  
[Info@howardgroupinc.com](mailto:Info@howardgroupinc.com)  
[www.howardgroupinc.com](http://www.howardgroupinc.com)